Predictive Oncology (POAI) announced additions to its leadership team and Board of Directors in support of the Company’s new digital asset treasury strategy focused on the Aethir, ATH, token. The Company announced that Shawn Matthews, CEO of DNA Holdings Venture, has joined its Board of Directors; Thomas McLaughlin, CIO of DNA Holdings Venture, has joined the leadership team as Chief Investment Officer; and biopharmaceutical veteran Sara Turken, JD, has joined as the Company’s new General Counsel.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
- Predictive Oncology Closes $343.5M Private Placements
- Predictive Oncology Enters Securities Purchase Agreements
- Predictive Oncology Inc trading halted, news pending
- Predictive Oncology Announces $344.4M Private Placements
- Predictive Oncology prices private placements to initiate digital asset treasury